1. Maxwell MH, Breed ES, Schwartz IL: Renal venous pressure in chronic congestive heart failure. J Clin Invest 1950;29:342-348
2. Mullens W, Abrahams Z, Francis GS, et al: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-596
3. Damman K, van Deursen VM, Navis G, et al: Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-588
4. Ross EA: Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail 2012;18:930-938
5. Guazzi M, Gatto P, Giusti G, et al: Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart- kidney interaction. Int J Cariol 2013;169:379-384
6. Burnett JC Jr, Knox FG: Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 1980;238:F279-F282
7. Doty JM, Saggi BH, Sugerman HJ, et al: Effect of increased renal venous pressure on renal function. J Trauma 1999;47:1000-1003
8. Burnett JC Jr, Haas JA, Knox FG: Segmental analysis of sodium reabsorption during renal vein constriction. Am J Physiol 1982;243:F19-F22
9. Shimada S, Hirose T, Takahashi C, et al: Pathophysiological and molecular mechanisms involved in renal congestion in a novel rat model. Sci Rep 2018;8:16808
10. Wear JB Jr: Ligation of the inferior vena cava above the renal veins. J Urol 1961;86:301-303
11. Wald H, Popovtzer MM: Renal function and Na- K-ATPase in rats after suprarenal ligation of inferior vena cava. Pflugers Arch 1982;394:165-173
12. Heldin, CH, Westermark B, Wasteson A: Platelet-derived growth factor: purification and partial characterization. Proc Natl Acad Sci USA 1979;76:3722- 3726
13. Ek B, Heldin CH: Characterization of a tyrosine-specific kinase activity in human fibroblast membranes stimulated by patelet-derived growth factor. J Biol Chem 1982;257:10486-10492
14. Waterfield MD, Scrace GT, Whittle N, et al: Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983;304:35-39
15. Kanakaraj P, Raj S, Khan SA, et al: Ligand-induced interaction between alpha- and beta-type platelet-derived growth factor (PDGF) receptors: role of receptor heterodimers in kinase activation. Biochemistry 1991;30:1761-1767
16. Kelly HD, Haldeman BA, Grant FJ, et al: Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans- phosphorylation. J Biol Chem 1991;266:8987-8992
17. Koch CA, Anderson D, Moran MF, et al: SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 1991;252:668-674
18. Hellstrom M, Kaeln M, Lindahl P, et al: Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Develoment 1999;126:3047-3055
19. Lindahl P, Johansson BR, Leveen P, et al: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-245
20. Leveen P, Pekny M, Gebre-Medhin S, et al: Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994;8:1875-1887
21. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15:275-286
22. Betsholtz C: Biology of platelet-derived growth factors in development. Birth Defects Res C Embryo Today 2003;69:272-285
23. Raica M, Cimpean AM: Platelet-derived growth factor (PDGF)/ PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 2010;3:572-599
24. Zeisberg M, Kalluri R: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol 2013;304:C216-C225
25. Campanholle G, Ligresti G, Gharib SA, et al: Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol 2013;304:C591-C603
26. Schrimpf C, Teebken OE, Wilhelmi M, et al: The role of pericyte detachment in vascular rarefaction. J Vasc Res 2014;51:247-258
27. Cops J, Mullens W, Verbrugge FH, et al: Selective abdominal venous congestion induces adverse renal and hepatic morphological and functional alterations despite a preserved cardiac function. Sci Rep 2018;8:17757
28. Kennedy-Lydon TM, Crawford C, Wildman SS, et al: Renal pericytes: regulators of medullary blood flow. Acta Physiol. 2013;207:212–25
29. Castellano G, Franzin R, Stasi A, et al: Complement activation during ischemia/reperfusion injury induces pericyte-myofibroblast transdifferentiation regulating peritubular capillary lumen reduction through pERK signaling. Front Immunol 2018;9:1002
30. Humphreys BD, Lin SL, Kobayashi A, et al: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85-97
31. Kramann R, DiRocco DP, Humphreys BD: Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol 2013;231:273-289
32. Iyoda M, Shibata T, Wada Y, et al: Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti- glomerular basement membrane nephritis. Nephrol Dial Transplant 2013;28:576- 584
33. Iyoda M, Shibata T, Kawaguchi M, et al: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int 2009;75:1060-1070
34. Graciano ML, Mitchell KD: Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 2012;302:F60-F69
35. Liu Y, Shi G, Yee H, et al: Shenkang injection, a modern preparation of Chinese patent medicine, diminishes tubulointerstitial fibrosis in obstructive nephropathy via targeting pericyte-myofibroblast transition. Am J Transl Res 2019;11:1980- 1996
36. Roskoski R Jr: Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res 2019;144:19-50
37. Papadopoulos N, Lennartsson J: The PDGF/PDGFR pathway as a drug target. Mol Aspects Med 2018;62:75-88
38. Galanis A, Ma H, Rajkhowa T, et al: Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014;123:94-100
39. 平上 陸、中富 靖、水口 純: フィブロネクチンの欠損マウス．血栓止血誌 1998;9:467-470
40. Pankov R, Yamada KM: Fibronectin at a glance. J Cell Sci 2002;115:3861-3863
41. Yang L, Brooks CR, Xiao S, et al: KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest 2015;125:1620-1636
42. Simonson MS: Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 2007;71:846-854
43. Fu H, Tian Y, Zhou L, et al: Tenascin-C is a majar component of the fibrogenic niche in kidney fibrosis. J Am Soc Nephrol 2017;28:785-801
44. Chen S, Fu H, Wu S, et al: Tenascin-C protects against acute kidney injury by recruiting Wnt ligands. Kidney Int 2019;95:62-74
45. Icer MA, Gezmen-Karadag M: The multiple functions and mechanisms of osteopontin. Clin Biochem 2018;59:17-24
46. 塩井 淳、西沢 良貴、城野 修一 他: 血管石灰化におけるオステオポンチンの発現とその調節．動脈硬化 1997;24:547-550
47. Tsukui T, Ueha S, Abe J, et al: Qualitative rather than quantitative changes are hallmarks of fibroblasts in bleomycin-induced pulmonary fibrosis. Am J Pathol 2013;183:758-773
48. Liu CY, Lin HH, Tang MJ, et al: Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 2015;30:15966-15988
49. 大塚藤男 著・編、皮膚科学 第 9 版、金芳堂、2012、33-34
50. 籏持 淳: サイトカインと I 型コラーゲン遺伝子の転写調節．Connective Tissue 1996;28:197-204
51. Ohto-Fujita E, Konno T, Shimizu M, et al: Hydrolyzed eggshell membrane immobilized on phosphorylcholine polymer supplies extracellular matrix environment for human dermal fibroblasts. Cell Tissue Res 2011;345:177-190
52. Tang N, Zhang Y, Liang Q, et al: The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats. Mol Med Rep 2018;17:3837-3844
53. Balkwill FR, Burke F: The cytokine network. Immunol Today 1989;10:299-304
54. Makino K, Makino T, Stawski L, et al: Blockade of PDGF receptors by crenolanib has therapeutic effect in patient fibroblasts and in preclinical models of systemic sclerosis. J Invest Dermatol 2017;137:1671-1681
55. Aldeiri B, Roostalu U, Albertini A, et al: Transgelin-expressing myofibroblasts orchestrate ventral midline closure through TGF β signaling. Development 2017;144:3336-3348
56. Liu R, Hossain MM, Chen X, et al: Mechanoregulation of SM22α/Transgelin. Biochemistry 2017;56:5526-5538
57. Kramann R, Humphreys BD: Kidney pericytes: roles in regeneration and fibrosis. 2014;34:374-383
58. Musgrove EA, Caldon CE, Barraclough J, et al: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-572
59. Joa H, Blazevic T, Grojer C, et al: Tylophorine reduces protein biosynthesis and rapidly decreases cyclin D1, inhibiting vascular smooth muscle cell proliferation in vitro and in organ culture. Phytomedicine 2019;60:152938
60. Kim WY, Nam SA, Song HC, et al: The role of autophagy in unilateral ureteral obstruction rat model. Nephrology 2012;17:148-159
61. Kim JI, Jung KJ, Jang HS, et al: Gender-specific role of HDAC11 in kidney ischemia- and reperfusion-induced PAI-1 expression and injury. Am J Physiol Renal Physiol 2013;305:F61-F70
62. Kawai S, Takagi Y, Kurosawa T: Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp Anim 2011;60:481-487
63. Wang S, Wilkes MC, Leof EB, et al: Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 2005;19:1-11
64. Melaiu O, Catalano C, De Santi C, et al: Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
65. Ichii O, Nakamura T, Irie T, et al: Close pathological correlations between chronic kidney disease and reproductive organ-associated abnormalities in female cotton rats. Exp Biol Med (Maywood) 2018;243:418-427
66. Sun Y, Yu H, Zheng D, et al: Sudan black B reduces autofluorescence in urine renal tissue. Arch Pathol Lab Med 2011;135:1335-1342
67. Perrien DS, Saleh MA, Keiko T, et al: Novel methods for microCT-based analyses of vasculature in the renal cortex reveal a loss of perfusable arterioles and glomeruli in eNOX-/- mice. BMC nephrology 2016:17:24. DOI:10.1186/s12882-016-0235- 5
68. Yilmaz M, Lahoti A, O’Brien S, et al: Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 2015;121:3894-3904
69. François H, Coppo P, Hayman JP, et al: Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 2008;51:298-301
70. Emadi E, Abdoli N, Ghanbarinejad V, et al: The potential role of mitochondrial impairment in the pathogenesis of imatinib-induced renal injury. Heliyon 2019;5:e01996
71. Sun YB, Qu X, Caruana G, et al: The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. Differentiation 2016;92:102-107
72. Xianyuan L, WeiZ, Yaqian D, et al: Anti-renal fibrosis effect of asperulosidic acid via TGF-β1/smad2/smad3 and NF- κ B signaling pathways in a rat model of unilateral ureteral obstruction. Phytomedicine 2019;53:274-285
73. Zhang ZH, He JQ, Qin WW, et al: Biomarkers of obstructive nephropathy using a metabolomics approach in rat. Chem Biol Interact 2018;296:229-239
74. LeeJW, Chou CL, Knepper MA: Deep sequencing in microdissected renal tubules identifies nephron segment-sepecific transcriptomes. J Am Soc Nephrol 2015;26:2669-2677
75. Buchdunger E, O’Reilly T, Wood J: Pharmacology of imatinib (STI571). Eur J Cancer 2002;38:S28-S36
76. Gilbert RE, Kelly DJ, Mckay T, et al: PDGF signal transduction inhibition ameliorates experimental proliferative glomerulonephritis. Kidney Int 2001;59:1324-1332
77. Lassila M, Jandeleit-Dahm K, Seah KK, et al: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005;16:363- 373
78. Sadanaga A, Nakashima H, Masutani K, et al: Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 2005;52:3987-3996
79. Zoja C, Corna D, Rottoli D, et al: Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kideny Int 2006;70:97-103
80. Iyoda M, Hudkins KL, Becker-Herman S, et al: Suppression of cryoglobulinemia and secondary membranoproliferative glomerulonephritis by imatinib. J Am Soc Nephrol 2009;20:68-77
81. Savikko J, Taskinen E, Von Willebrand E: Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003;75:1147-1153
82. Elmholdt TR, Buus NH, Ramsing M, et al: Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. Journal of the European Academy of Dermatology and Venereology 2013;27:779-784
83. 山川 聡: ネフローゼ症候群に伴う特発性急性腎障害 (NSAKI)の主要な病態は腎実質浮腫である． 日児腎誌 2016;29:114-121
論文の公開元へ
